Fig 1.
Consort diagram of data sources and derivation of strongyloidiasis cohort (n = 691).
Fig 2.
Interaction between three pre-treatment laboratory components of strongyloidiasis diagnosis: microscopic identification of larvae, Strongyloides serology result, and presence of eosinophilia (n = 691).
* Includes 60 participants with only stool positive, 5 with stool and other sample positive, and 4 with only other sample positive. @ Overall 608 / 691 (88%) of individuals diagnosed with strongyloidiasis had preceding eosinophilia.
Table 1.
Pre-treatment characteristics of strongyloidiasis cohort (n = 691).
Fig 3.
Sequential proportions of strongyloidiasis cohort by ‘positive’ and ‘equivocal’ diagnosis, ivermectin treatment received, and treatment outcomes, including sub-categorisation of ‘treatment success’ (n = 691).
Table 2.
Multiple logistic regression model of likelihood of ivermectin prescription by ethnicity, adjusted for potential confounding factors (n = 691).
Table 3.
Proportion of positive, equivocal and negative S. stercoralis serology among participants with pre-treatment serology testing, by region and country of birth (n = 2629).